Melgaço JG, Soriani FM, Sucupira PHF, Pinheiro LA, Vieira YR, de Oliveira JM, Lewis-Ximenez LL, Araújo CCV, Pacheco-Moreira LF, Menezes GB, Cruz OG, Vitral CL, Pinto MA. Changes in cellular proliferation and plasma products are associated with liver failure. World J Hepatol 2016; 8(32): 1370-1383 [PMID: 27917263 DOI: 10.4254/wjh.v8.i32.1370]
Corresponding Author of This Article
Juliana Gil Melgaço, PhD, Instituto Oswaldo Cruz/Fiocruz, Laboratório de Desenvolvimento Tecnológico em Virologia, Fundação Oswaldo Cruz/FIOCRUZ, Avenida Brasil, 4365, pavilhão Hélio e Peggy Pereira, Rio de Janeiro 21040-900, Brazil. juliana.melgaco@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 4 Variables from the mitogen-stimulated peripheral blood mononuclear cell phenotypes from patients with acute hepatitis A infection and healthy subjects
Phenotypes/cytokines (PHA/LPS)
HC (n = 10)
AH (n = 8)
ALF (n = 8)
HC vs AH
HC vs ALF
AH vs ALF
PI of CD3+
133.1 ± 71.12
44.4 ± 25.83
17.48 ± 5.94
0.0155
0.0021
0.0426
(95.19-171.0)
(22.80-65.99)
(11.24-23.72)
CD4+CD25+FoxP3+ (%)
17.23 ± 9.74
17.08 ± 5.37
5.99 ± 2.80
ns
0.0009
0.0003
(12.03-22.42)
(12.59-21.57)
(3.65-8.33)
CD4+CD29+CD44+ (%)
38.63 ± 18.37
20.75 ± 7.82
10.22 ± 4.74
0.0062
< 0.0001
0.0047
(28.84-48.42)
(14.21-27.29)
(6.25-14.18)
CD8+CD29+CD44+ (%)
39.76 ± 19.91
37.56 ± 25.01
9.03 ± 4.59
ns
0.0002
0.0104
(29.15-50.36)
(16.74-58.57)
(5.18-12.88)
CD3-CD56+CD16- (%)
8.31 ± 6.75
4.19 ± 2.28
0.50 ± 0.37
ns
0.0006
0.0009
(2.07-14.56)
(2.08-6.30)
(0.15-0.84)
CD3-CD56lowCD16+ (%)
12.70 ± 8.93
8.52 ± 5.68
1.11 ± 0.66
ns
0.0012
0.0018
(4.44-20.96)
(3.26-13.78)
(0.50-1.72)
CD3+CD56+CD16+ (%)
13.66 ± 3.54
7.20 ± 5.28
1.83 ± 1.06
0.0117
< 0.0001
0.0070
(11.77-15.55)
(2.79-11.63)
(0.94-2.72)
IL-6 (pg/mL)
2625.33 ± 3320
565.7 ± 313.3
156.8 ± 173.9
0.0155
< 0.0001
0.0070
(856.5-4394)
(303.8-827.6)
(11.40-302.2)
TNFα (pg/mL)
1675.20 ± 623.4
1405.0 ± 324.3
145.3 ± 107.9
ns
< 0.0001
0.0002
(1343-2007)
(1134-1676)
(55.09-235.5)
IL-10 (pg/mL)
528.86 ± 755.1
269.5 ± 145.8
188.4 ± 267.1
ns
0.0454
ns
(126.5-931.2)
(147.6-391.5)
(-16.88-393.7)
IFNγ (pg/mL)
3379.1 ± 1869
2467.0 ± 2787
1249.0 ± 2067
ns
0.0205
ns
(2383-4375)
(137.1-4798)
(-479.2-2977)
IL-8 (pg/mL)
273.9 ± 116.3
274.2 ± 148.5
151.0 ± 156.4
ns
0.0205
0.0379
(211.9-335.9)
(150.0-398.3)
(20.21-281.8)
IL-17 (pg/mL)
73.81 ± 107.0
31.55 ± 35.58
4.16 ± 3.20
ns
0.0029
0.0116
(16.81-130.8)
(1.80-61.30)
(1.49-6.84)
Table 5 Variables from hepatitis A virus Ag-stimulated peripheral blood mononuclear cell phenotypes from patients with acute hepatitis A infection and healthy subjects
Phenotypes/cytokines (HAVAg)
HC (n = 10)
AH (n = 8)
ALF (n = 8)
HC vs AH
HC vs ALF
AH vs ALF
PI of CD3+
1.09 ± 0.85
3.15 ± 1.92
3.34 ± 2.29
0.0053
0.0044
ns
(0.64-1.55)
(1.54-4.76)
(1.42-5.25)
CD4+CD25+FoxP3+ (%)
0.85 ± 0.96
1.0 ± 0.97
3.19 ± 1.49
ns
0.0011
0.0070
(0.34-1.37)
(0.18-1.81)
(1.95-4.44)
CD4+CD29+CD44+ (%)
11.99 ± 6.43
27.93 ± 8.16
5.46 ± 5.92
0.0008
0.0077
0.0006
(8.55-15.42)
(21.1-34.76)
(0.50-10.42)
CD8+CD29+CD44+ (%)
12.65 ± 4.31
30.13 ± 6.74
36.05 ± 10.59
0.0001
0.0001
ns
(10.35-14.95)
(24.49-35.77)
(27.19-44.90)
CD3-CD56+CD16- (%)
0.19 ± 0.20
0.30 ± 0.19
1.33 ± 0.85
ns
0.0009
0.0005
(0.05-0.34)
(0.13-0.46)
(0.62-2.04)
CD3-CD56lowCD16+ (%)
4.28 ± 2.22
10.09 ± 8.94
14.24 ± 11.81
ns
ns
ns
(2.70-5.87)
(2.61-17.5)
(4.36-24.12)
CD3+CD56+CD16+ (%)
1.67 ± 2.71
4.25 ± 4.06
15.06 ± 7.74
0.0110
0.0003
0.0019
(0.22-3.12)
(0.85-7.65)
(8.58-21.53)
IL-6 (pg/mL)
50.49 ± 76.14
76.41 ± 93.18
139.7 ± 165.9
ns
ns
ns
(9.92-91.06)
(-1.46-154.3)
(0.98-278.4)
TNFα (pg/mL)
92.49 ± 133.4
23.96 ± 28.92
1.63 ± 1.01
ns
0.0089
0.0098
(21.42-163.6)
(-0.21-48.14)
(0.78-2.48)
IL-10 (pg/mL)
10.39 ± 13.97
52.78 ± 62.06
164.3 ± 75.56
0.0297
0.0001
0.0148
(2.94-17.84)
(0.89-104.7)
(101.1-227.5)
IFNγ (pg/mL)
0.88 ± 1.08
106.6 ± 183.9
1095 ± 1962
0.0035
0.0001
0.0499
(0.30-1.46)
(-47.14-260.4)
(-546-2735)
IL-8 (pg/mL)
88.64 ± 45.40
148.9 ± 54.77
150.2 ± 72.19
0.0131
0.0110
ns
(64.44-112.8)
(103.1-194.7)
(89.84-210.5)
IL-17 (pg/mL)
3.36 ± 3.75
32.61 ± 38.30
7.58 ± 5.43
0.0008
ns
0.0499
(1.36-5.36)
(0.59-64.64)
(3.05-12.13)
Table 6 Variables from mitogen-stimulated peripheral blood mononuclear cells from non-viral acute hepatitis patients and healthy control subjects
Phenotypes/cytokines (PHA/LPS)
HC (n = 10)
AH (n = 8)
ALF (n = 5)
HC vs AH
HC vs ALF
AH vs ALF
PI of CD3+
133.1 ± 71.12
173.3 ± 91.84
268.4 ± 101.6
ns
ns
ns
(95.19-171.0)
(96.51-250.1)
(142.3-394.5)
CD4+CD25+FoxP3+ (%)
17.23 ± 9.74
15.82 ± 8.13
6.84 ± 5.12
ns
ns
ns
(12.03-22.42)
(9.02-22.62)
(0.48-13.2)
CD4+CD29+CD44+ (%)
38.63 ± 18.37
21.84 ± 7.50
36.67 ± 14.54
ns
ns
ns
(28.84-48.42)
(15.56-28.11)
(18.61-54.73)
CD8+CD29+CD44+(%)
39.76 ± 19.91
22.26 ± 11.16
29.59 ± 15.21
ns
ns
ns
(29.15-50.36)
(12.92-31.59)
(10.71-48.47)
CD3-CD56+CD16- (%)
8.31 ± 6.75
6.33 ± 4.13
17.22 ± 4.94
ns
0.0289
0.0030
(2.07-14.56)
(2.88-9.79)
(13.09-21.35)
CD3-CD56lowCD16+ (%)
12.70 ± 8.93
11.38 ± 4.67
27.66 ± 3.49
ns
0.0061
0.007
(4.44-20.96)
(7.05-15.71)
(22.11-33.21)
CD3+CD56+CD16+ (%)
13.66 ± 3.54
11.63 ± 3.01
8.52 ± 4.97
ns
ns
ns
(11.77-15.55)
(9.11-14.15)
(2.35-14.70)
IL-6 (pg/mL)
2625.33 ± 3320
966 ± 622.6
1309 ± 851.6
ns
ns
ns
(856.5-4394)
(445.5-1486.0)
(251.60-2366)
TNFα (pg/mL)
1675.20 ± 623.4
1497 ± 219.8
3217 ± 991.5
ns
0.0044
0.0016
(1343-2007)
(1313-1681)
(1986-4448)
IL-10 (pg/mL)
528.86 ± 755.1
217.1 ± 159.1
152.1 ± 126.4
ns
ns
ns
(126.5-931.2)
(84.12-350.2)
(-4.89-309.0)
IFNγ (pg/mL)
3379.1 ± 1869
2257 ± 2872
1378 ± 2533
ns
ns
ns
(2383-4375)
(-143.3-4658)
(-1767-4524)
IL-8 (pg/mL)
273.9 ± 116.3
293.9 ± 120.2
733.1 ± 404.8
ns
0.0267
ns
(211.9-335.9)
(193.4-394.4)
(230.4-1236)
IL-17 (pg/mL)
73.81 ± 107.0
36.31 ± 34.62
62.73 ± 5.78
ns
ns
ns
(16.81-130.8)
(7.36-65.25)
(55.55-69.91)
Citation: Melgaço JG, Soriani FM, Sucupira PHF, Pinheiro LA, Vieira YR, de Oliveira JM, Lewis-Ximenez LL, Araújo CCV, Pacheco-Moreira LF, Menezes GB, Cruz OG, Vitral CL, Pinto MA. Changes in cellular proliferation and plasma products are associated with liver failure. World J Hepatol 2016; 8(32): 1370-1383